Journal
SKELETAL BIOLOGY AND MEDICINE
Volume 1192, Issue -, Pages 81-83Publisher
BLACKWELL PUBLISHING
DOI: 10.1111/j.1749-6632.2009.05228.x
Keywords
glucocorticoids; osteoporosis; bone fragility
Categories
Funding
- NIAMS NIH HHS [P50 AR063043, K24 AR048841, R01 AR043052] Funding Source: Medline
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR063043, K24AR048841, R01AR043052] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Glucocorticoid (GC) use results in rapid bone loss and an elevated risk of fracture. The excess bone fragility from GC treatment is multifactorial. GCs increase bone remodeling through reductions in gonadal hormones, elevations in PTH from negative calcium balance, early stimulation of osteoclast maturation and activity, and delayed, sustained reduction in osteogenesis and osteoblast activity. GCs also alter the metabolism of osteocytes so that increased osteocyte lacunae size, with demineralization around the osteocyte and reduced elastic modulus, is observed in a mouse model of GC-induced bone loss. In summary, GC effects on bone fragility are multifactorial, and additional studies are now under way to clarify how GCs alter osteocyte metabolism and result in reduction in localized bone strength.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available